|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some of these shared susceptibility loci regulate the expression of relevant genes involved in NCC formation and developmental processes (such as <i>BARD1,</i><i>MSX1,</i> and <i>SHOX2</i>) and are enriched in several epigenetic markers from NB and fetal heart cell lines.
|
31480262 |
2019 |
|
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low-level expression of full-length BARD1 associated with advanced neuroblastoma.
|
30132831 |
2018 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further evidence for a dualistic role came with the identification of BARD1 as a neuroblastoma predisposition gene in our genome wide association study which has demonstrated that single nucleotide polymorphisms in BARD1 can correlate with risk or can protect against cancer based on their association with the expression of FL and splice variants of BARD1.
|
29292755 |
2017 |
|
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Citalopram drastically decreased the expression of MYBL2, BIRC5 and BARD1 poor prognosis factors of neuroblastoma with fold-changes of -107 (p<2.26 10-7), -24.1 (p<5.6 10-9) and -17.7 (p<1.2 10-7).
|
28467792 |
2017 |
|
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CHD9, a cancer driver gene, was the most significantly altered (4.0% of cases) after ALK.Other genes (PTK2, NAV3, NAV1, FZD1 and ATRX), expressed in neuroblastoma and involved in cell invasion and migration were mutated at frequency ranged from 4% to 2%.Focal adhesion and regulation of actin cytoskeleton pathways, were frequently disrupted (14.1% of cases) thus suggesting potential novel therapeutic strategies to prevent disease progression.Notably BARD1, CHEK2 and AXIN2 were enriched in rare, potentially pathogenic, germline variants.In summary, whole exome and deep targeted sequencing identified novel cancer genes of clinically aggressive neuroblastoma.
|
27009842 |
2016 |
|
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the BARD1 rs6435862 T>G and rs3768716 A>G polymorphisms may contribute to increased susceptibility to neuroblastoma, especially for the subjects at age ≥12 months, with adrenal gland-originated or with late clinical stage neuroblastoma.
|
26941572 |
2016 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By using the ICSNPathway to analyze neuroblastoma GWAS data, 15 candidate SNPs, 10 genes including IL3, BARD1, and CFL, and 31 pathways were identified that might contribute to the susceptibility of patients to neuroblastoma.
|
24293394 |
2014 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provide further evidence that the risk loci identified in GWA studies contribute to NB susceptibility in distinct populations and strengthen the role of BARD1 as major genetic contributor to NB risk.
|
23222812 |
2013 |
|
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common BARD1 SNPs affect risk of neuroblastoma in African-Americans.
|
22328350 |
2012 |
|
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
|
22350409 |
2012 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our genome-wide association study (GWAS) has identified common variants within FLJ22536, BARD1, and LMO1 as significantly associated with neuroblastoma and more robustly associated with high-risk disease.
|
21436895 |
2011 |
|
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data show that common variation in BARD1 contributes to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma.
|
19412175 |
2009 |